首页 > 最新文献

Infectious disorders drug targets最新文献

英文 中文
SARS-CoV-2 Infection and Severity in Patients with Hematologic Malignancies: A Systematic Review. 血液系统恶性肿瘤患者的SARS-CoV-2感染及其严重程度:一项系统综述
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526523666230502142256
SeyedAhmad SeyedAlinaghi, Amirali Karimi, Pegah Mirzapour, Roghayeh Salmani, Armin Razi, Hengameh Mojdeganlou, Paniz Mojdeganlou, Mohammad Qodrati, Reyhaneh Jashaninejad, Parinaz Paranjkhoo, Omid Dadras, Besharat Zarezadeh, Amir Masoud Afsahi, Arian Afzalian, Sanaz Varshochi, Esmaeil Mehraeen, Ghazaleh Afsahi

Introduction: Earlier reports described the possibility of higher SARS-CoV-2 infection and severity in patients with hematological malignancies. Given the importance and incidence of these malignancies, we aimed to systematically review SARS-CoV-2 infection and severity in patients with hematologic cancers.

Methods: We retrieved the relevant records by searching the keywords in online databases of PubMed, Web of Science, Cochrane, and Scopus on December 31st, 2021. A two-step screening; title/abstract and full-text screening, was employed to select the eligible studies. These eligible studies entered the final qualitative analysis. The study is adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist to ensure the reliability and validity of the results.

Results: Forty studies concerning different hematologic malignancies and the effect of COVID-19 infection on them were included in the final analysis. The findings showed that in general, the prevalence of SARS-CoV-2 infection and the severity of the disease are often higher in hematologic malignancies and the patients could experience higher morbidity and mortality compared to general populations.

Conclusion: It appeared that individuals with hematologic malignancies are more vulnerable to COVID-19 infection and they experience more severe disease with higher mortality rates. The presence of other comorbidities could also deteriorate this situation. Further investigation is recommended to evaluate the outcome of COVID-19 infection in different subtypes of hematologic malignancies.

早期的报告描述了血液系统恶性肿瘤患者中更高的SARS-CoV-2感染和严重程度的可能性。鉴于这些恶性肿瘤的重要性和发病率,我们旨在系统地回顾血液病患者的SARS-CoV-2感染和严重程度。方法:于2021年12月31日在PubMed、Web of Science、Cochrane、Scopus等在线数据库中检索关键词,检索相关记录。两步筛选;采用标题/摘要和全文筛选,选择符合条件的研究。这些合格的研究进入最后的定性分析。本研究遵循系统评价和荟萃分析首选报告项目(PRISMA)清单,以确保结果的可靠性和有效性。结果:共纳入40项不同血液学恶性肿瘤及COVID-19感染对其影响的研究。研究结果表明,总体而言,血液恶性肿瘤患者的SARS-CoV-2感染患病率和疾病严重程度往往更高,与普通人群相比,患者的发病率和死亡率可能更高。结论:血液学恶性肿瘤患者更易感染COVID-19,病情更严重,死亡率更高。其他合并症的存在也可能使这种情况恶化。建议进一步调查以评估不同亚型血液恶性肿瘤中COVID-19感染的结果。
{"title":"SARS-CoV-2 Infection and Severity in Patients with Hematologic Malignancies: A Systematic Review.","authors":"SeyedAhmad SeyedAlinaghi,&nbsp;Amirali Karimi,&nbsp;Pegah Mirzapour,&nbsp;Roghayeh Salmani,&nbsp;Armin Razi,&nbsp;Hengameh Mojdeganlou,&nbsp;Paniz Mojdeganlou,&nbsp;Mohammad Qodrati,&nbsp;Reyhaneh Jashaninejad,&nbsp;Parinaz Paranjkhoo,&nbsp;Omid Dadras,&nbsp;Besharat Zarezadeh,&nbsp;Amir Masoud Afsahi,&nbsp;Arian Afzalian,&nbsp;Sanaz Varshochi,&nbsp;Esmaeil Mehraeen,&nbsp;Ghazaleh Afsahi","doi":"10.2174/1871526523666230502142256","DOIUrl":"https://doi.org/10.2174/1871526523666230502142256","url":null,"abstract":"<p><strong>Introduction: </strong>Earlier reports described the possibility of higher SARS-CoV-2 infection and severity in patients with hematological malignancies. Given the importance and incidence of these malignancies, we aimed to systematically review SARS-CoV-2 infection and severity in patients with hematologic cancers.</p><p><strong>Methods: </strong>We retrieved the relevant records by searching the keywords in online databases of PubMed, Web of Science, Cochrane, and Scopus on December 31st, 2021. A two-step screening; title/abstract and full-text screening, was employed to select the eligible studies. These eligible studies entered the final qualitative analysis. The study is adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist to ensure the reliability and validity of the results.</p><p><strong>Results: </strong>Forty studies concerning different hematologic malignancies and the effect of COVID-19 infection on them were included in the final analysis. The findings showed that in general, the prevalence of SARS-CoV-2 infection and the severity of the disease are often higher in hematologic malignancies and the patients could experience higher morbidity and mortality compared to general populations.</p><p><strong>Conclusion: </strong>It appeared that individuals with hematologic malignancies are more vulnerable to COVID-19 infection and they experience more severe disease with higher mortality rates. The presence of other comorbidities could also deteriorate this situation. Further investigation is recommended to evaluate the outcome of COVID-19 infection in different subtypes of hematologic malignancies.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 7","pages":"29-38"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10107298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19: Potassium Contributes to Pathologies that Cause Disability. COVID-19:钾有助于导致残疾的病理。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526523666230529163610
Ziad Fajloun, Yingliang Wu, Zhijian Cao, Hervé Kovacic, Jean-Marc Sabatier
{"title":"COVID-19: Potassium Contributes to Pathologies that Cause Disability.","authors":"Ziad Fajloun,&nbsp;Yingliang Wu,&nbsp;Zhijian Cao,&nbsp;Hervé Kovacic,&nbsp;Jean-Marc Sabatier","doi":"10.2174/1871526523666230529163610","DOIUrl":"https://doi.org/10.2174/1871526523666230529163610","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 7","pages":"39-41"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10577124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Docking Analysis of Adhatoda vasica with Thromboxane A2 Receptor (TXA2R) (6IIU) and Antiviral Molecules for Possible Dengue Complications. 血管瓣蟾与血栓素A2受体(TXA2R) (6iu)及登革热可能并发症抗病毒分子的分子对接分析
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526522666220718101544
Pugazhenthan Thangaraju, Gopinathan N, Vijayakumar Ar, Meenalochini Prakash Gurunthalingam, Sree Sudha Ty, Sajitha Venkatesan, Eswaran Thangaraju

Objective: The present study is an in silico model of platelet amplification potential of Adhatoda vasica, which can be used to treat thrombocytopenia in dengue complications.

Methods: Docking studies have proved to be an essential tool that facilitates the structural diversity of natural products to be harnessed in an organized manner. In the present study, vasicine containing natural anti-dengue potential was subjected to docking studies using Schrodinger glides software (ver.11.1). The docking study was carried out to find out the potential molecular targets for selected protein. The docking was carried out on different ligands, like vasicine, ramatroban, chloroquine, celgosivir, and standard eltrombopag downloaded from PubChem and retrieved to glide software and ligands prepared using lig prep wizard. Docking was performed using the ligand docking wizard of Glide-maestro 2018.

Results: The docking score of vasicine (-5.27) is nearly identical to the standard eltrombopag (-6.08), and both ligands bind with one hydrogen bond. The validation score of ramatroban is -12.39, binding with five hydrogen bonds, Celgosivir exhibited a docking score of -7.3 with three hydrogen bonds, and chloroquine displayed no hydrogen bond but had a docking score of -4.6.

Conclusion: Vasicine was found to be the most suitable target of platelet amplification potential from Adhatoda vasica. However, the molecular docking results are preliminary, and it has been indicated that vasicine could be one of the potential ligands to treat the thrombocytopenia of dengue; experimental evaluation will be carried out in the near future.

目的:建立血管瓣血小板扩增电位的计算机模型,用于治疗登革热合并血小板减少症。方法:对接研究已被证明是促进天然产物结构多样性以有组织的方式利用的重要工具。在本研究中,利用薛定谔滑行软件(版本11.1)对含有天然抗登革热潜能的瓦西里疫苗进行对接研究。对接研究是为了寻找所选蛋白的潜在分子靶点。对接不同的配体,如从PubChem下载的vasicine、ramatroban、chloroquine、celgosivir和标准的eltrombopag,并检索到滑翔软件和使用light prep wizard制备的配体。对接使用Glide-maestro 2018的配体对接向导进行。结果:vasicine的对接分数(-5.27)与标准的eletrombopag的对接分数(-6.08)几乎相同,并且两种配体都与一个氢键结合。拉马托班的验证评分为-12.39,与5个氢键结合,Celgosivir与3个氢键的对接评分为-7.3,氯喹没有氢键,但对接评分为-4.6。结论:Vasicine是最合适的血小板扩增电位靶点。然而,分子对接结果是初步的,表明vasicine可能是治疗登革热血小板减少症的潜在配体之一;实验评估将在不久的将来进行。
{"title":"Molecular Docking Analysis of <i>Adhatoda vasica</i> with Thromboxane A<sub>2</sub> Receptor (TXA<sub>2</sub>R) (6IIU) and Antiviral Molecules for Possible Dengue Complications.","authors":"Pugazhenthan Thangaraju,&nbsp;Gopinathan N,&nbsp;Vijayakumar Ar,&nbsp;Meenalochini Prakash Gurunthalingam,&nbsp;Sree Sudha Ty,&nbsp;Sajitha Venkatesan,&nbsp;Eswaran Thangaraju","doi":"10.2174/1871526522666220718101544","DOIUrl":"https://doi.org/10.2174/1871526522666220718101544","url":null,"abstract":"<p><strong>Objective: </strong>The present study is an in silico model of platelet amplification potential of Adhatoda vasica, which can be used to treat thrombocytopenia in dengue complications.</p><p><strong>Methods: </strong>Docking studies have proved to be an essential tool that facilitates the structural diversity of natural products to be harnessed in an organized manner. In the present study, vasicine containing natural anti-dengue potential was subjected to docking studies using Schrodinger glides software (ver.11.1). The docking study was carried out to find out the potential molecular targets for selected protein. The docking was carried out on different ligands, like vasicine, ramatroban, chloroquine, celgosivir, and standard eltrombopag downloaded from PubChem and retrieved to glide software and ligands prepared using lig prep wizard. Docking was performed using the ligand docking wizard of Glide-maestro 2018.</p><p><strong>Results: </strong>The docking score of vasicine (-5.27) is nearly identical to the standard eltrombopag (-6.08), and both ligands bind with one hydrogen bond. The validation score of ramatroban is -12.39, binding with five hydrogen bonds, Celgosivir exhibited a docking score of -7.3 with three hydrogen bonds, and chloroquine displayed no hydrogen bond but had a docking score of -4.6.</p><p><strong>Conclusion: </strong>Vasicine was found to be the most suitable target of platelet amplification potential from Adhatoda vasica. However, the molecular docking results are preliminary, and it has been indicated that vasicine could be one of the potential ligands to treat the thrombocytopenia of dengue; experimental evaluation will be carried out in the near future.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 1","pages":"e180722206836"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10699770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Biochemical, Serological and Immunological Tests for Diagnosis of Coronavirus Disease 2019 (COVID-19) Patients: A Comprehensive Systematic Review and Meta-analysis. 生化、血清学和免疫学检测诊断2019冠状病毒病(COVID-19)患者:一项综合系统评价和荟萃分析
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526523666230228144910
Milad Azami, Amirreza Jamshidbeigi, Hadi Esmaeili Gouvarchin Ghaleh, Reza Ranjbar

Background: Recent studies have suggested the role of primary laboratory tests in addition to clinical symptoms for patients suspected to have coronavirus disease 2019 (COVID-19), which play a significant role in the diagnosis of COVID-19. However, the results of these studies are contradictory. The present study was conducted to evaluate biochemical, serological, and immunological tests for the diagnosis of COVID-19 patients.

Methods: This study was presented in accordance with the PRISMA protocol. This protocol is registered with the code CRD42019145410 in PROSPERO. We conducted a comprehensive literature search in databases, including Web of Science, PubMed/Medline, CINAHL Scopus, Cochrane Library, EMBASE, Science Direct, and EBSCO to find citations from the beginning of January 2019 until the beginning of April 2020 without any restrictions.

Results: Finally, 51 studies, including 5,490 COVID-19 patients, were included in the present metaanalysis. The prevalence of different factors observed in laboratory findings was as follows: the prevalence of lymphopenia in patients with COVID-19 accounted for 51.6% (95% CI: 44.0-59.1), elevated C-reactive protein (CRP) was 63.6% (95% CI: 57.0-69.8), elevated erythrocyte sedimentation rate (ESR) was 62.5% (95% CI: 50.1-73.5), elevated tumor necrosis factor alpha (TNFα) was 28.7% (95% CI: 9.0-62.1), elevated serum amyloid-A level was 74.7% (95% CI: 50.0-89.7), elevated procalcitonin level was 72.6% (95% CI: 58.1-83.5), elevated interleukin-6 level was 59.9% (95% CI: 48.2-70.5), reduced CD3 level was 68.3% (95% CI: 50.1-82.2), reduced CD4 level was 62.0% (95% CI: 51.1- 71.6), elevated lactate dehydrogenase (LDH) level accounted for 53.1% (95% CI: 43.6-62.4), elevated brain natriuretic peptide (BNP) accounted for 48.9% (95% CI: 30.4-67.7), reduced albumin and reduced pre-albumin levels in patients with COVID-19 were estimated to be 54.7% (95% CI: 38.1-70.2) and 49.0% (95% CI: 26.6-71.8), and D-dimer level was 44.9% (95% CI: 31.0-59.6).

Conclusion: The results show lymphopenia, elevated ESR level, elevated CRP level, elevated serum amyloid-A, elevated TNFα, elevated procalcitonin level, elevated interleukin-6 level, reduced CD3, reduced CD4, elevated BNP, elevated LDH, reduced albumin, reduced pre-albumin, and elevated Ddimer levels as the most common findings at the time of admission.

背景:近期研究提示,除临床症状外,初级实验室检查对疑似COVID-19患者的诊断具有重要意义。然而,这些研究的结果是矛盾的。本研究旨在评估生化、血清学和免疫学检测对COVID-19患者的诊断价值。方法:本研究按照PRISMA方案进行。该协议在PROSPERO中注册代码为CRD42019145410。我们在Web of Science、PubMed/Medline、CINAHL Scopus、Cochrane Library、EMBASE、Science Direct和EBSCO等数据库中进行了全面的文献检索,查找了2019年1月初至2020年4月初的引文,没有任何限制。结果:最终,51项研究,包括5490名COVID-19患者,被纳入本荟萃分析。实验室检查中不同因素的患病率如下:COVID-19患者淋巴细胞减少率占51.6% (95% CI: 44.0 ~ 59.1), c反应蛋白(CRP)升高占63.6% (95% CI: 57.0 ~ 69.8),红细胞沉降率(ESR)升高占62.5% (95% CI: 50.1 ~ 73.5),肿瘤坏死因子α (TNFα)升高占28.7% (95% CI: 9.0 ~ 62.1),血清淀粉样蛋白a升高占74.7% (95% CI:50.0 ~ 89.7),降钙素原升高72.6% (95% CI: 58.1 ~ 83.5),白介素-6升高59.9% (95% CI: 48.2 ~ 70.5), CD3降低68.3% (95% CI: 50.1 ~ 82.2), CD4降低62.0% (95% CI: 51.1 ~ 71.6),乳酸脱氢酶(LDH)升高53.1% (95% CI: 43.6 ~ 62.4),脑钠肽(BNP)升高48.9% (95% CI:30.4-67.7), COVID-19患者白蛋白和白蛋白前水平降低估计为54.7% (95% CI: 38.1-70.2)和49.0% (95% CI: 26.6-71.8), d -二聚体水平为44.9% (95% CI: 31.0-59.6)。结论:淋巴细胞减少、ESR水平升高、CRP水平升高、血清淀粉样蛋白-a升高、TNFα升高、降钙素原水平升高、白细胞介素-6水平升高、CD3降低、CD4降低、BNP升高、LDH升高、白蛋白降低、前白蛋白降低、二聚体水平升高是入院时最常见的表现。
{"title":"Biochemical, Serological and Immunological Tests for Diagnosis of Coronavirus Disease 2019 (COVID-19) Patients: A Comprehensive Systematic Review and Meta-analysis.","authors":"Milad Azami,&nbsp;Amirreza Jamshidbeigi,&nbsp;Hadi Esmaeili Gouvarchin Ghaleh,&nbsp;Reza Ranjbar","doi":"10.2174/1871526523666230228144910","DOIUrl":"https://doi.org/10.2174/1871526523666230228144910","url":null,"abstract":"<p><strong>Background: </strong>Recent studies have suggested the role of primary laboratory tests in addition to clinical symptoms for patients suspected to have coronavirus disease 2019 (COVID-19), which play a significant role in the diagnosis of COVID-19. However, the results of these studies are contradictory. The present study was conducted to evaluate biochemical, serological, and immunological tests for the diagnosis of COVID-19 patients.</p><p><strong>Methods: </strong>This study was presented in accordance with the PRISMA protocol. This protocol is registered with the code CRD42019145410 in PROSPERO. We conducted a comprehensive literature search in databases, including Web of Science, PubMed/Medline, CINAHL Scopus, Cochrane Library, EMBASE, Science Direct, and EBSCO to find citations from the beginning of January 2019 until the beginning of April 2020 without any restrictions.</p><p><strong>Results: </strong>Finally, 51 studies, including 5,490 COVID-19 patients, were included in the present metaanalysis. The prevalence of different factors observed in laboratory findings was as follows: the prevalence of lymphopenia in patients with COVID-19 accounted for 51.6% (95% CI: 44.0-59.1), elevated C-reactive protein (CRP) was 63.6% (95% CI: 57.0-69.8), elevated erythrocyte sedimentation rate (ESR) was 62.5% (95% CI: 50.1-73.5), elevated tumor necrosis factor alpha (TNFα) was 28.7% (95% CI: 9.0-62.1), elevated serum amyloid-A level was 74.7% (95% CI: 50.0-89.7), elevated procalcitonin level was 72.6% (95% CI: 58.1-83.5), elevated interleukin-6 level was 59.9% (95% CI: 48.2-70.5), reduced CD3 level was 68.3% (95% CI: 50.1-82.2), reduced CD4 level was 62.0% (95% CI: 51.1- 71.6), elevated lactate dehydrogenase (LDH) level accounted for 53.1% (95% CI: 43.6-62.4), elevated brain natriuretic peptide (BNP) accounted for 48.9% (95% CI: 30.4-67.7), reduced albumin and reduced pre-albumin levels in patients with COVID-19 were estimated to be 54.7% (95% CI: 38.1-70.2) and 49.0% (95% CI: 26.6-71.8), and D-dimer level was 44.9% (95% CI: 31.0-59.6).</p><p><strong>Conclusion: </strong>The results show lymphopenia, elevated ESR level, elevated CRP level, elevated serum amyloid-A, elevated TNFα, elevated procalcitonin level, elevated interleukin-6 level, reduced CD3, reduced CD4, elevated BNP, elevated LDH, reduced albumin, reduced pre-albumin, and elevated Ddimer levels as the most common findings at the time of admission.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 7","pages":"42-65"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10112024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hand, Foot, and Mouth Disease Outbreak What You Need to Know. 手足口病爆发你需要知道的
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526523666230601121101
Amandeep Singh, Okesanya Olalekan John, Bello Barakat Bisola

HFMD is an obvious disease in children mostly below the age of five constituting a public health challenge to Asian-Pacific and developing countries majorly. This disease is often caused by enterovirus 71 (EV71) and Coxsackievirus A16. HFMD is a mild degree fever and general illness which manifests for about 10 days. Young age, male gender, poor hygiene, and high social contacts are some risk factors. HFMD can be diagnosed clinically by isolating the virus from stool and pharynx and identifying it on Light microscopic examination. Polymerase Chain Reaction Assay is a gold standard for confirming the virus from swabbed lesions. Late confirmation could lead to severe complications. There are no specific treatments and vaccines licensed for general use in the treatment of various serotypes of HFMD. The major strategy to prevent and control this disease is to strictly follow the WHO 8 guidelines to curb the spread of the disease.

手足口病是一种常见于5岁以下儿童的明显疾病,主要对亚太地区和发展中国家构成公共卫生挑战。该病通常由肠病毒71型(EV71)和柯萨奇病毒A16引起。手足口病是一种轻度发烧和一般疾病,症状约为10天。年轻、男性、卫生条件差和社会交往频繁是一些危险因素。手足口病可通过从粪便和咽中分离病毒,并在光镜检查下识别。聚合酶链反应试验是从拭子病变中确认病毒的金标准。晚确认可能导致严重的并发症。目前还没有专门的治疗方法和疫苗被许可用于治疗各种血清型手足口病。预防和控制这种疾病的主要战略是严格遵守世卫组织8项指导方针,以遏制疾病的传播。
{"title":"Hand, Foot, and Mouth Disease Outbreak What You Need to Know.","authors":"Amandeep Singh,&nbsp;Okesanya Olalekan John,&nbsp;Bello Barakat Bisola","doi":"10.2174/1871526523666230601121101","DOIUrl":"https://doi.org/10.2174/1871526523666230601121101","url":null,"abstract":"<p><p>HFMD is an obvious disease in children mostly below the age of five constituting a public health challenge to Asian-Pacific and developing countries majorly. This disease is often caused by enterovirus 71 (EV71) and Coxsackievirus A16. HFMD is a mild degree fever and general illness which manifests for about 10 days. Young age, male gender, poor hygiene, and high social contacts are some risk factors. HFMD can be diagnosed clinically by isolating the virus from stool and pharynx and identifying it on Light microscopic examination. Polymerase Chain Reaction Assay is a gold standard for confirming the virus from swabbed lesions. Late confirmation could lead to severe complications. There are no specific treatments and vaccines licensed for general use in the treatment of various serotypes of HFMD. The major strategy to prevent and control this disease is to strictly follow the WHO 8 guidelines to curb the spread of the disease.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 7","pages":"77-81"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10116877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leprosy Reactions: Clinical Pharmacologist Perspective with Repurposed Medications. 麻风病反应:临床药理学家的观点与重新用途的药物。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526522666220907125114
Pugazhenthan Thangaraju, Aravind Kumar B, Hemasri Velmurugan, Sajitha Venkatesan, SreeSudha Ty

The elimination of leprosy has been possible with the available anti-leprotic drugs. However, the lepra reactions usually occur months or years after multi-drug therapy completion, and continue to be a formidable challenge mainly owing to its role in causing nerve damage and disability. Corticosteroids are commonly used but they lead to systemic complications, and hence require dose reduction and adjunct therapy with a different target. Various drugs with different targets have been identified and are in practice to treat lepra reactions. The newer targets can include genetic and tissue targets in the skin and nerve. Thalidomide treatment reducing pentraxin-3, toll-like receptor antagonists, minocycline, apremilast, immunomodulators, and tenidap can be helpful in lepra reaction. Other modalities to manage lepra reactions include plasma exchange, intravenous immunoglobulins, and immunotherapy. Most of these treatments are based only on the pathological process of the reaction and tend to be incomplete leading to recurrence. Newer multimodal approaches are required based on various biomarkers (genetic, tissue, serological), which can be monitored to prevent the recurrence of reactions. Hence, there is a need for newer targets and drugs to be identified for the management of lepra reactions.

有了现有的抗麻风药物,就有可能消灭麻风。然而,麻风反应通常发生在多种药物治疗完成后数月或数年,主要由于其引起神经损伤和残疾的作用,仍然是一个艰巨的挑战。通常使用皮质类固醇,但它们会导致全身性并发症,因此需要减少剂量并以不同的目标进行辅助治疗。已经确定了具有不同靶点的各种药物,并在实践中用于治疗麻风反应。新的目标包括皮肤和神经中的基因和组织目标。沙利度胺治疗减少戊曲辛-3、toll样受体拮抗剂、米诺环素、阿普米司特、免疫调节剂和替尼达可有助于麻风反应。其他治疗麻风反应的方法包括血浆置换、静脉注射免疫球蛋白和免疫治疗。这些治疗大多只基于反应的病理过程,往往是不完整的,导致复发。需要基于各种生物标志物(遗传、组织、血清学)的新的多模式方法,这些生物标志物可以监测以防止反应复发。因此,有必要确定新的靶点和药物来管理麻风反应。
{"title":"Leprosy Reactions: Clinical Pharmacologist Perspective with Repurposed Medications.","authors":"Pugazhenthan Thangaraju,&nbsp;Aravind Kumar B,&nbsp;Hemasri Velmurugan,&nbsp;Sajitha Venkatesan,&nbsp;SreeSudha Ty","doi":"10.2174/1871526522666220907125114","DOIUrl":"https://doi.org/10.2174/1871526522666220907125114","url":null,"abstract":"<p><p>The elimination of leprosy has been possible with the available anti-leprotic drugs. However, the lepra reactions usually occur months or years after multi-drug therapy completion, and continue to be a formidable challenge mainly owing to its role in causing nerve damage and disability. Corticosteroids are commonly used but they lead to systemic complications, and hence require dose reduction and adjunct therapy with a different target. Various drugs with different targets have been identified and are in practice to treat lepra reactions. The newer targets can include genetic and tissue targets in the skin and nerve. Thalidomide treatment reducing pentraxin-3, toll-like receptor antagonists, minocycline, apremilast, immunomodulators, and tenidap can be helpful in lepra reaction. Other modalities to manage lepra reactions include plasma exchange, intravenous immunoglobulins, and immunotherapy. Most of these treatments are based only on the pathological process of the reaction and tend to be incomplete leading to recurrence. Newer multimodal approaches are required based on various biomarkers (genetic, tissue, serological), which can be monitored to prevent the recurrence of reactions. Hence, there is a need for newer targets and drugs to be identified for the management of lepra reactions.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 2","pages":"e070922208607"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9765404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Identification of Virulence Markers and Phylogenetic Groups' Association, and Antimicrobial Susceptibility of Uropathogenic Escherichia coli Isolates. 尿路致病性大肠杆菌毒力标记、系统进化群关联及药敏研究。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526522666220908161529
Dahbia Yasmina Meziani, Nicolas Barnich, Anouar Boucheham, Mohamed Larbi Rezgoune, Kaddour Benlabed, Michael Rodrigues, Dalila Satta
BACKGROUNDUrinary tract infections represent a world public health problem, which is caused mainly by Uropathogenic Escherichia coli. Although, they are originally found in the intestinal microbiota in the majority of the cases, urinary tract infections can also be caused by intra-intestinal pathogenic E. coli.OBJECTIVEThe main objective of our research is to identify the virulence factors generally associated with different pathotypes across phylogenetic groups.METHODSE. coli were isolated from patients with urinary tract infections. Antimicrobial susceptibility tests, virulence genes and phylogroups were prospected. The data analysis were performed using the chi-square and Fisher exact test.RESULTSIn total, 72.2% of isolates were showed multidrug resistant. We have also depicted an important association between E. coli from inpatients with UTIs and pap and hlyA genes (p-0.041 and p-0.019 respectively). The predominant phylogenetic group in our isolates is B2 (45.4%) followed by D (12.4%). Our results showed that 9.3% of isolates have an unknown phylogroup which show a significant association with astA gene (p-0.008). We have as well find a significant association between B2 and three virulence genes namely pap, hlyA and invE (p-0.002, p-0.001, p-0.025 respectively); B1 and pap, hlyA genes (p-0.049 and p-0.021 respectively); E and afa gene (p-0.024).CONCLUSIONCertain virulence factors have been shown to be potential targets for drug design and therapeutic pathways in order to deal with the antimicrobial resistance problem enhanced by antibiotic therapy.
背景:尿路感染是一个世界性的公共卫生问题,主要由尿路致病性大肠杆菌引起。虽然在大多数情况下,它们最初是在肠道微生物群中发现的,但尿路感染也可能由肠道内致病性大肠杆菌引起。目的:我们研究的主要目的是确定与不同系统发育群不同病理类型相关的毒力因子。方法:从尿路感染患者中分离大肠杆菌。对其药敏试验、毒力基因和系统群进行了展望。数据分析采用卡方检验和Fisher精确检验。结果:72.2%的分离株出现多重耐药。我们还描述了尿路感染住院患者的大肠杆菌与pap和hlyA基因之间的重要关联(分别为p-0.041和p-0.019)。系统发育类群以B2(45.4%)居多,其次为D(12.4%)。结果显示,9.3%的分离株具有未知的系统群,该系统群与astA基因显著相关(p-0.008)。我们还发现B2与pap、hlyA和invE三个毒力基因显著相关(分别为p-0.002、p-0.001和p-0.025);B1和pap、hlyA基因(p-0.049和p-0.021);E和afa基因(p-0.024)。结论:某些毒力因子已被证明是药物设计和治疗途径的潜在靶点,以解决抗生素治疗增加的耐药性问题。
{"title":"Identification of Virulence Markers and Phylogenetic Groups' Association, and Antimicrobial Susceptibility of Uropathogenic <i>Escherichia coli</i> Isolates.","authors":"Dahbia Yasmina Meziani,&nbsp;Nicolas Barnich,&nbsp;Anouar Boucheham,&nbsp;Mohamed Larbi Rezgoune,&nbsp;Kaddour Benlabed,&nbsp;Michael Rodrigues,&nbsp;Dalila Satta","doi":"10.2174/1871526522666220908161529","DOIUrl":"https://doi.org/10.2174/1871526522666220908161529","url":null,"abstract":"BACKGROUND\u0000Urinary tract infections represent a world public health problem, which is caused mainly by Uropathogenic Escherichia coli. Although, they are originally found in the intestinal microbiota in the majority of the cases, urinary tract infections can also be caused by intra-intestinal pathogenic E. coli.\u0000\u0000\u0000OBJECTIVE\u0000The main objective of our research is to identify the virulence factors generally associated with different pathotypes across phylogenetic groups.\u0000\u0000\u0000METHODS\u0000E. coli were isolated from patients with urinary tract infections. Antimicrobial susceptibility tests, virulence genes and phylogroups were prospected. The data analysis were performed using the chi-square and Fisher exact test.\u0000\u0000\u0000RESULTS\u0000In total, 72.2% of isolates were showed multidrug resistant. We have also depicted an important association between E. coli from inpatients with UTIs and pap and hlyA genes (p-0.041 and p-0.019 respectively). The predominant phylogenetic group in our isolates is B2 (45.4%) followed by D (12.4%). Our results showed that 9.3% of isolates have an unknown phylogroup which show a significant association with astA gene (p-0.008). We have as well find a significant association between B2 and three virulence genes namely pap, hlyA and invE (p-0.002, p-0.001, p-0.025 respectively); B1 and pap, hlyA genes (p-0.049 and p-0.021 respectively); E and afa gene (p-0.024).\u0000\u0000\u0000CONCLUSION\u0000Certain virulence factors have been shown to be potential targets for drug design and therapeutic pathways in order to deal with the antimicrobial resistance problem enhanced by antibiotic therapy.","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 2","pages":"e080922208695"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9765407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Study of Antibacterial Effect of Nigella sativa Seed Extracts on Bacterial Isolates from Cases of Wound Infection. 黑草种子提取物对伤口感染分离菌抑菌作用的研究。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526523666230403095441
Boinu Babu, Pooja Rao, Ethel Suman, Jeppu Udayalaxmi

Background: With an increasing trend of pathogenic bacteria developing resistance to the existing drugs, there is a need for newer therapeutic measures. Nigella sativa seeds and oil have been used for decades as Ayurveda, Unani Tibb and other forms of traditional medicine for various disorders. Thymoquinone is one of the active components of the N. sativa seeds.

Objective: The present study determines the antibacterial effect of crude methanolic extract N. sativa seeds and thymoquinone against bacteria causing wound infection.

Methods: Samples obtained from cases of wound infection received at a Microbiology laboratory attached to a tertiary care hospital over a period of six months were included in the study. The antibacterial effect of crude methanolic extract of N. sativa seeds was determined by the Punch Well method. The minimum inhibitory concentration (MIC) of thymoquinone against bacteria isolated from cases of wound infection was determined by the Micro Broth Dilution technique.

Results: A total of 60 isolates were collected from 60 samples of wound infection. By the Punch Well method, Staphylococcus aureus showed varying zones of inhibition whereas all gram-negative bacilli and Enterococcus faecalis did not show any zone of inhibition. Thymoquinone showed good antibacterial activity against S. aureus with MIC values ranging from 2-8μg/ml for most of the isolates. Uniformly, MIC of thymoquinone against all gram-negative bacilli and E. faecalis was >128μg/ml, p<0.001. It was found that methicillin-resistant S. aureus (MRSA) isolates showed higher MIC than methicillin sensitive S. aureus (MSSA) isolates p<0.05.

Conclusion: Antibacterial activity of thymoquinone was very good against S. aureus but showed limited activity against Enterobacteriaceae members and E. faecalis isolated from patients with wound infection. Thymoquinone may be considered a potential antibacterial agent against wound infection caused by S. aureus.

背景:随着病原菌对现有药物产生耐药性的趋势日益增加,需要新的治疗措施。几十年来,黑草种子和油一直被用作阿育吠陀、乌尼提布和其他形式的传统药物,用于治疗各种疾病。百里醌是sativa种子的有效成分之一。目的:研究芥蓝种子粗甲醇提取物和百里醌对伤口感染细菌的抑菌作用。方法:从一家三级医院附属微生物实验室接收的伤口感染病例中获得的样本在六个月内被纳入研究。采用冲孔法测定了芥蓝种子粗甲醇提取物的抑菌效果。采用微肉汤稀释法测定百里醌对伤口感染病原菌的最低抑菌浓度。结果:从60例伤口感染病例中共分离到60株细菌。Punch Well法对金黄色葡萄球菌有不同的抑制区,而对革兰氏阴性杆菌和粪肠球菌均无抑制区。百里醌对金黄色葡萄球菌具有良好的抑菌活性,多数菌株的MIC值在2 ~ 8μg/ml之间。结论:百里醌对金黄色葡萄球菌具有良好的抑菌活性,但对伤口感染患者分离的肠杆菌科细菌和粪肠杆菌的抑菌活性有限。百里醌可能被认为是一种潜在的抗金黄色葡萄球菌引起的伤口感染的抗菌剂。
{"title":"A Study of Antibacterial Effect of <i>Nigella sativa</i> Seed Extracts on Bacterial Isolates from Cases of Wound Infection.","authors":"Boinu Babu,&nbsp;Pooja Rao,&nbsp;Ethel Suman,&nbsp;Jeppu Udayalaxmi","doi":"10.2174/1871526523666230403095441","DOIUrl":"https://doi.org/10.2174/1871526523666230403095441","url":null,"abstract":"<p><strong>Background: </strong>With an increasing trend of pathogenic bacteria developing resistance to the existing drugs, there is a need for newer therapeutic measures. Nigella sativa seeds and oil have been used for decades as Ayurveda, Unani Tibb and other forms of traditional medicine for various disorders. Thymoquinone is one of the active components of the N. sativa seeds.</p><p><strong>Objective: </strong>The present study determines the antibacterial effect of crude methanolic extract N. sativa seeds and thymoquinone against bacteria causing wound infection.</p><p><strong>Methods: </strong>Samples obtained from cases of wound infection received at a Microbiology laboratory attached to a tertiary care hospital over a period of six months were included in the study. The antibacterial effect of crude methanolic extract of N. sativa seeds was determined by the Punch Well method. The minimum inhibitory concentration (MIC) of thymoquinone against bacteria isolated from cases of wound infection was determined by the Micro Broth Dilution technique.</p><p><strong>Results: </strong>A total of 60 isolates were collected from 60 samples of wound infection. By the Punch Well method, Staphylococcus aureus showed varying zones of inhibition whereas all gram-negative bacilli and Enterococcus faecalis did not show any zone of inhibition. Thymoquinone showed good antibacterial activity against S. aureus with MIC values ranging from 2-8μg/ml for most of the isolates. Uniformly, MIC of thymoquinone against all gram-negative bacilli and E. faecalis was >128μg/ml, p<0.001. It was found that methicillin-resistant S. aureus (MRSA) isolates showed higher MIC than methicillin sensitive S. aureus (MSSA) isolates p<0.05.</p><p><strong>Conclusion: </strong>Antibacterial activity of thymoquinone was very good against S. aureus but showed limited activity against Enterobacteriaceae members and E. faecalis isolated from patients with wound infection. Thymoquinone may be considered a potential antibacterial agent against wound infection caused by S. aureus.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 5","pages":"e030423215400"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9844210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial Resistance Patterns of Gram-negative Bacteria in an Iranian Referral Pediatric Hospital: A Present Danger of New Delhi Metallo-β- lactamase. 伊朗转诊儿科医院革兰氏阴性菌的抗菌素耐药模式:新德里金属β-内酰胺酶的当前危险。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526523666230418114213
Shima Mahmoudi, Babak Pourakbari, Maryam Rostamyan, Hojatollah Raji, Reihaneh Hosseinpour Sadeghi, Setareh Mamishi

Background: Antimicrobial resistance among gram-negative bacteria has been growing, particularly in developing countries, like Iran. The emergence and spread of carbapenem-resistance mechanisms is a major public health concern because no definite treatments have yet been established for this problem. This study aimed to evaluate antibiotic susceptibility of gram-negative bacteria, metallo-β-lactamases (MBLs) and carbapenemase-producing genes, including bla NDM, bla VIM, and bla IMP in patients referred to Children's Medical Center, Tehran, Iran.

Material and methods: In this cross-sectional study, a total of 944 gram-negative isolates were tested in the study, and antimicrobial susceptibility testing was performed. Moreover, MBL production of carbapenem-resistant isolates, as well as the presence of bla NDM, bla VIM, and bla IMP, was investigated.

Results: The most common gram-negative isolated bacteria were Escherichia coli (489 samples, 52%), followed by Klebsiella pneumoniae (167 samples, 18%), Pseudomonas aeruginosa (101 samples, 11%), Enterobacter spp. (64 samples, 7%), Pseudomonas spp. (35 samples, 4%), Acinetobacter baumannii (18 samples, 2%), and Burkholderia cepacia (17 samples, 2%). Imipenemresistant was found in 75%, 61%, and 60% of Stenotrophomonas maltophilia, Enterobacter spp., and A. baumannii isolates, respectively. Moreover, the highest resistance to meropenem was observed in S. maltophilia, A. baumannii, P. aeruginosa, and B. cepacia (100%, 96%, 83%, and 61.5%, respectively). Double disk synergy test (DDST) results showed that 112 out of 255 carbapenem- resistant isolates (44%) were MBL-producing ones. The presence of the bla NDM gene was identified in 32 (29%) of MBL-producing isolates, 13 of which were K. pneumoniae, 7 P. aeruginosa, and 7 E. coli, 3 Enterobacter spp., and 2 Klebsiella spp., respectively. The presence of the bla IMP and bla VIM genes was detected in 2 (2%) and 1 (1%) of MBL-producing isolates. These genes were detected in only MBL-producing P. aeruginosa isolates.

Conclusion: Our findings suggest the emergence of NDM-producing strains in our hospital, and bla NDM was the most frequently detected carbapenemase gene in MBL-producing P. aeruginosa, K. pneumoniae, and Klebsiella spp. Since such bacteria can easily spread among patients in the hospital, a strong infection control and prevention plan is highly recommended.

背景:革兰氏阴性菌的抗微生物药物耐药性一直在增长,特别是在伊朗等发展中国家。碳青霉烯耐药机制的出现和传播是一个主要的公共卫生问题,因为目前还没有确定的治疗方法来解决这个问题。本研究旨在评估伊朗德黑兰儿童医疗中心转诊患者的革兰氏阴性菌、金属β-内酰胺酶(MBLs)和碳青霉烯酶产生基因(包括bla NDM、bla VIM和bla IMP)的抗生素敏感性。材料与方法:本横断面研究共检测革兰氏阴性菌株944株,并进行药敏试验。此外,还研究了碳青霉烯耐药菌株的MBL产量,以及bla NDM、bla VIM和bla IMP的存在。结果:最常见的革兰氏阴性分离菌为大肠埃希菌(489份,52%),其次为肺炎克雷伯菌(167份,18%)、铜绿假单胞菌(101份,11%)、肠杆菌(64份,7%)、假单胞菌(35份,4%)、鲍曼不动杆菌(18份,2%)、洋葱伯克氏菌(17份,2%)。嗜麦芽窄养单胞菌、肠杆菌和鲍曼不动杆菌分离株分别有75%、61%和60%对亚胺培南耐药。对美罗培南耐药率最高的菌种为嗜麦芽球菌(S. maltopophilia)、鲍曼杆菌(A. baumannii)、铜绿假单胞菌(P. aeruginosa)和洋葱球菌(B. cepacia),分别为100%、96%、83%和61.5%。双盘协同试验(DDST)结果显示,255株碳青霉烯类耐药菌株中有112株(44%)为产mbl菌株。在32株(29%)产生mbl的分离株中检测到bla NDM基因,其中肺炎克雷伯菌13株,铜绿假单胞菌7株,大肠杆菌7株,肠杆菌3株,克雷伯菌2株。bla IMP和bla VIM基因分别在2个(2%)和1个(1%)产生mbl的分离株中检测到。这些基因仅在产生mbl的铜绿假单胞菌分离株中检测到。结论:我院出现了产NDM的菌株,bla NDM是产NDM的铜绿假单胞菌、肺炎克雷伯菌中检出最多的碳青霉烯酶基因,该菌易在院内患者中传播,建议制定强有力的感染控制和预防方案。
{"title":"Antimicrobial Resistance Patterns of Gram-negative Bacteria in an Iranian Referral Pediatric Hospital: A Present Danger of New Delhi Metallo-β- lactamase.","authors":"Shima Mahmoudi,&nbsp;Babak Pourakbari,&nbsp;Maryam Rostamyan,&nbsp;Hojatollah Raji,&nbsp;Reihaneh Hosseinpour Sadeghi,&nbsp;Setareh Mamishi","doi":"10.2174/1871526523666230418114213","DOIUrl":"https://doi.org/10.2174/1871526523666230418114213","url":null,"abstract":"<p><strong>Background: </strong>Antimicrobial resistance among gram-negative bacteria has been growing, particularly in developing countries, like Iran. The emergence and spread of carbapenem-resistance mechanisms is a major public health concern because no definite treatments have yet been established for this problem. This study aimed to evaluate antibiotic susceptibility of gram-negative bacteria, metallo-β-lactamases (MBLs) and carbapenemase-producing genes, including bla <sub>NDM</sub>, bla <sub>VIM</sub>, and bla <sub>IMP</sub> in patients referred to Children's Medical Center, Tehran, Iran.</p><p><strong>Material and methods: </strong>In this cross-sectional study, a total of 944 gram-negative isolates were tested in the study, and antimicrobial susceptibility testing was performed. Moreover, MBL production of carbapenem-resistant isolates, as well as the presence of bla <sub>NDM</sub>, bla <sub>VIM</sub>, and bla <sub>IMP</sub>, was investigated.</p><p><strong>Results: </strong>The most common gram-negative isolated bacteria were Escherichia coli (489 samples, 52%), followed by Klebsiella pneumoniae (167 samples, 18%), Pseudomonas aeruginosa (101 samples, 11%), Enterobacter spp. (64 samples, 7%), Pseudomonas spp. (35 samples, 4%), Acinetobacter baumannii (18 samples, 2%), and Burkholderia cepacia (17 samples, 2%). Imipenemresistant was found in 75%, 61%, and 60% of Stenotrophomonas maltophilia, Enterobacter spp., and A. baumannii isolates, respectively. Moreover, the highest resistance to meropenem was observed in S. maltophilia, A. baumannii, P. aeruginosa, and B. cepacia (100%, 96%, 83%, and 61.5%, respectively). Double disk synergy test (DDST) results showed that 112 out of 255 carbapenem- resistant isolates (44%) were MBL-producing ones. The presence of the bla <sub>NDM</sub> gene was identified in 32 (29%) of MBL-producing isolates, 13 of which were K. pneumoniae, 7 P. aeruginosa, and 7 E. coli, 3 Enterobacter spp., and 2 Klebsiella spp., respectively. The presence of the bla <sub>IMP</sub> and bla <sub>VIM</sub> genes was detected in 2 (2%) and 1 (1%) of MBL-producing isolates. These genes were detected in only MBL-producing P. aeruginosa isolates.</p><p><strong>Conclusion: </strong>Our findings suggest the emergence of NDM-producing strains in our hospital, and bla NDM was the most frequently detected carbapenemase gene in MBL-producing P. aeruginosa, K. pneumoniae, and Klebsiella spp. Since such bacteria can easily spread among patients in the hospital, a strong infection control and prevention plan is highly recommended.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 6","pages":"e180423215994"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10399827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resistance Pattern in Mostly Gram-negative Bacteria Causing Urinary Tract Infections. 大多数革兰氏阴性菌引起尿路感染的耐药模式。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526522666220928115043
Bader S Alotaibi, Bilal Ahmad Tantry, Anjum Farhana, Muath A Alammar, Naveed Nazir Shah, Abdul Hafeez Mohammed, Farooq Wani, Altaf Bandy

Purpose: The antimicrobial prescription in urinary tract infections (UTI) is driven by local data on its pathogenic spectrum and the resistance pattern exhibited by the disease-causing pathogens. We aimed to determine the bacteriological diversity of UTI causing pathogens and antimicrobial resistance in mostly gram-negative bacteria.

Methods: This retrospective hospital-based cross-sectional study analyzed the culture and sensitivity reports of urine samples from a referral centre in the Aljouf region of Saudi Arabia. All the antibiograms from January 1, 2020, to December 31st 2020, were included. The bacterial identification and antimicrobial testing were carried out by the BD Phoenix system (BD Diagnostics, Sparks, MD, USA). Antimicrobial testing was performed as per the Clinical and Laboratory Standard Institute recommendations. Frequencies of multidrug- and extensive drug resistance were calculated.

Results: Of the 1334 non-duplicate urine samples received, 422 (31.6%) bacterial growths were observed. Of these, 383 (90.8%) and 39 (9.2%) were gram-negative and gram-positive bacterial isolations, respectively. E. coli 161 (38.1%), K. pneumoniae 97 (23.0%), and E. faecalis 18 (4.3%) were frequent aetiologies of UTI. 309 (80.7%) of gram-negative bacteria were multidrug-resistant including 88 (23.0%) extensively drug-resistant. Overall, a resistance rate of > 55 % to 1st through 4th generation cephalosporins was observed except for cefoxitin (43.7%). A resistance rate of 37.6% was observed towards carbapenems, with the lowest rate (34.0%) to meropenem.

Conclusion: Multi-drug resistant gram-negative bacteria dominate the pathogenic spectrum of UTI in the region. A high resistance rate to cephalosporins and carbapenems exists in gram-negative organisms, causing UTI.

目的:尿路感染(UTI)的抗菌药物处方是由当地的致病谱数据和致病病原体所表现出的耐药模式驱动的。我们的目的是确定尿路感染引起的病原体的细菌多样性和大多数革兰氏阴性菌的抗菌素耐药性。方法:这项以医院为基础的回顾性横断面研究分析了沙特阿拉伯Aljouf地区转诊中心尿液样本的培养和敏感性报告。纳入2020年1月1日至2020年12月31日的所有抗生素图。细菌鉴定和抗菌试验由BD Phoenix系统(BD Diagnostics, Sparks, MD, USA)进行。抗菌测试是按照临床和实验室标准研究所的建议进行的。计算了多药耐药和广泛耐药的频率。结果:收到的1334份非重复尿样中,有422份(31.6%)细菌生长。其中革兰氏阴性菌383株(90.8%),革兰氏阳性菌39株(9.2%)。大肠杆菌161(38.1%)、肺炎克雷伯菌97(23.0%)和粪肠杆菌18(4.3%)是尿路感染的常见病因。革兰氏阴性菌多重耐药309株(80.7%),广泛耐药88株(23.0%)。总体而言,除头孢西丁(43.7%)外,对第1 ~第4代头孢菌素的耐药率> 55%。对碳青霉烯类的耐药率为37.6%,对美罗培南的耐药率最低(34.0%)。结论:该地区尿路感染病原菌以多重耐药革兰氏阴性菌为主。革兰氏阴性菌对头孢菌素和碳青霉烯类具有较高的耐药率,可引起尿路感染。
{"title":"Resistance Pattern in Mostly Gram-negative Bacteria Causing Urinary Tract Infections.","authors":"Bader S Alotaibi,&nbsp;Bilal Ahmad Tantry,&nbsp;Anjum Farhana,&nbsp;Muath A Alammar,&nbsp;Naveed Nazir Shah,&nbsp;Abdul Hafeez Mohammed,&nbsp;Farooq Wani,&nbsp;Altaf Bandy","doi":"10.2174/1871526522666220928115043","DOIUrl":"https://doi.org/10.2174/1871526522666220928115043","url":null,"abstract":"<p><strong>Purpose: </strong>The antimicrobial prescription in urinary tract infections (UTI) is driven by local data on its pathogenic spectrum and the resistance pattern exhibited by the disease-causing pathogens. We aimed to determine the bacteriological diversity of UTI causing pathogens and antimicrobial resistance in mostly gram-negative bacteria.</p><p><strong>Methods: </strong>This retrospective hospital-based cross-sectional study analyzed the culture and sensitivity reports of urine samples from a referral centre in the Aljouf region of Saudi Arabia. All the antibiograms from January 1, 2020, to December 31st 2020, were included. The bacterial identification and antimicrobial testing were carried out by the BD Phoenix system (BD Diagnostics, Sparks, MD, USA). Antimicrobial testing was performed as per the Clinical and Laboratory Standard Institute recommendations. Frequencies of multidrug- and extensive drug resistance were calculated.</p><p><strong>Results: </strong>Of the 1334 non-duplicate urine samples received, 422 (31.6%) bacterial growths were observed. Of these, 383 (90.8%) and 39 (9.2%) were gram-negative and gram-positive bacterial isolations, respectively. E. coli 161 (38.1%), K. pneumoniae 97 (23.0%), and E. faecalis 18 (4.3%) were frequent aetiologies of UTI. 309 (80.7%) of gram-negative bacteria were multidrug-resistant including 88 (23.0%) extensively drug-resistant. Overall, a resistance rate of > 55 % to 1st through 4th generation cephalosporins was observed except for cefoxitin (43.7%). A resistance rate of 37.6% was observed towards carbapenems, with the lowest rate (34.0%) to meropenem.</p><p><strong>Conclusion: </strong>Multi-drug resistant gram-negative bacteria dominate the pathogenic spectrum of UTI in the region. A high resistance rate to cephalosporins and carbapenems exists in gram-negative organisms, causing UTI.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 2","pages":"e280922209238"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9830713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
Infectious disorders drug targets
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1